EMA Authorised: Etcamah (camizestrant) — AstraZeneca AB

View source ↗

Summary

Etcamah (camizestrant) has been authorised by EMA for the therapeutic area of breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• Etcamah (camizestrant)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: AstraZeneca AB. Decision date: 20/07/2026